Gregory Condie, DO
Interventional Pain Medicine · Murray, UTNPI 1255691986
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,027 of the $8,074 with a category attached, or 87.0%. It is spread thinly across 47 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations.
Across 345 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Medtronic$996
- Relievant Medsystems, Inc.$855
- AbbVie$673
- Collegium Pharmaceutical, Inc.$577
- Globus Medical$511
- plus $3K from 41 others
Across 9 payments — averaging $25,317 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GRT US Holding, Inc.$228K
What the payments were for
- Travel & lodging$1,04713%
- Food & beverage$7,02787%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$3,620
- INTELLIS ADAPTIVESTIM$390
- Lamitrode SCS Leads$370
- Mobi-C$121
How this compares
$8,074 in reported general payments places this provider in the 55th percentile of 26 interventional pain medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 19 | $22,276 |
| MovantikNaloxegol Oxalate | 38 | $18,003 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 362 | $16,007 |
| Aimovig AutoinjectorErenumab-Aooe | 21 | $15,102 |
| Oxycodone Hcl | 482 | $13,678 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 399 | $11,476 |
| Xtampza ErOxycodone Myristate | 16 | $9,786 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 46 | $9,137 |
| LinzessLinaclotide | 14 | $9,111 |
| Morphine Sulfate ErMorphine Sulfate | 240 | $7,691 |
| Fentanyl | 80 | $7,311 |
| Gabapentin | 329 | $6,973 |
| Buprenorphine Hcl | 111 | $5,923 |
| Pregabalin | 224 | $4,719 |
| Methadone Hcl | 77 | $1,975 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $12 | $18,00338 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $577 | $9,78616 claims |
| AbbVieLinzess | $673 | $9,11114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 26 interventional pain medicine providers in Utah.
Other interventional pain medicine in Murray
- Alex NelsonMurray$17K
- Kierra LawMurray$961
- Bryan HoelzerVineyard$718K
- Nathan ClementsSaint George$29K
- Rick ObraySt George$23K
- Brian RichardsonLogan$19K
- Steven LarsenSaint George$14K
- J Riley StringhamProvo$13K
- Craig DavisWest Jordan$13K
- Geeta NagpalWest Jordan$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.